Tags

Type your tag names separated by a space and hit enter

A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
J Clin Psychiatry 1996; 57(4):167-73JC

Abstract

BACKGROUND

This study was designed to determine if vitamin E is effective in reducing the severity of abnormal movements in patients with tardive dyskinesia (TD).

METHOD

Thirty-five patients completed a double-blind placebo-controlled parallel-group study of vitamin E. Seventeen of the patients were randomly assigned to receive 800 IU b.i.d. of vitamin E and 18 were assigned to placebo for 2 months. Twenty-nine patients had a diagnosis of schizophrenia and 6 of mood disorder. Patients were assessed using modified versions of the Abnormal Involuntary Movement Scale (mAIMS), Simpson-Angus Scale for extrapyramidal side effects, and Brief Psychiatric Rating Scale. Additionally, a subgroup of 23 patients were assessed using instrumental measurements of dyskinesia.

RESULTS

There was a significant reduction of dyskinesia in the vitamin E group, but not the placebo group, on both the mAIMS and the instrumental assessments. The overall reduction in mAIMS in the active group was 24%, with 5 (29%) of 17 patients demonstrating greater than 33% reduction in score. There was a greater reduction in mean mAIMS score (35%) with vitamin E in the subgroup of patients with TD for 5 years or less compared with the reduction (11%) in patients with TD for greater than 5 years. No change was observed in parkinsonism. In the patients with schizophrenia, there was a reduction in positive symptoms after vitamin E.

CONCLUSION

Vitamin E appears to be effective in reducing the severity of TD, especially in patients who have had TD for 5 years or less.

Authors+Show Affiliations

San Diego VA Medical Center, CA 92161, USA.No affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

8601552

Citation

Lohr, J B., and M P. Caligiuri. "A Double-blind Placebo-controlled Study of Vitamin E Treatment of Tardive Dyskinesia." The Journal of Clinical Psychiatry, vol. 57, no. 4, 1996, pp. 167-73.
Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry. 1996;57(4):167-73.
Lohr, J. B., & Caligiuri, M. P. (1996). A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. The Journal of Clinical Psychiatry, 57(4), pp. 167-73.
Lohr JB, Caligiuri MP. A Double-blind Placebo-controlled Study of Vitamin E Treatment of Tardive Dyskinesia. J Clin Psychiatry. 1996;57(4):167-73. PubMed PMID: 8601552.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. AU - Lohr,J B, AU - Caligiuri,M P, PY - 1996/4/1/pubmed PY - 1996/4/1/medline PY - 1996/4/1/entrez SP - 167 EP - 73 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 57 IS - 4 N2 - BACKGROUND: This study was designed to determine if vitamin E is effective in reducing the severity of abnormal movements in patients with tardive dyskinesia (TD). METHOD: Thirty-five patients completed a double-blind placebo-controlled parallel-group study of vitamin E. Seventeen of the patients were randomly assigned to receive 800 IU b.i.d. of vitamin E and 18 were assigned to placebo for 2 months. Twenty-nine patients had a diagnosis of schizophrenia and 6 of mood disorder. Patients were assessed using modified versions of the Abnormal Involuntary Movement Scale (mAIMS), Simpson-Angus Scale for extrapyramidal side effects, and Brief Psychiatric Rating Scale. Additionally, a subgroup of 23 patients were assessed using instrumental measurements of dyskinesia. RESULTS: There was a significant reduction of dyskinesia in the vitamin E group, but not the placebo group, on both the mAIMS and the instrumental assessments. The overall reduction in mAIMS in the active group was 24%, with 5 (29%) of 17 patients demonstrating greater than 33% reduction in score. There was a greater reduction in mean mAIMS score (35%) with vitamin E in the subgroup of patients with TD for 5 years or less compared with the reduction (11%) in patients with TD for greater than 5 years. No change was observed in parkinsonism. In the patients with schizophrenia, there was a reduction in positive symptoms after vitamin E. CONCLUSION: Vitamin E appears to be effective in reducing the severity of TD, especially in patients who have had TD for 5 years or less. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/8601552/A_double_blind_placebo_controlled_study_of_vitamin_E_treatment_of_tardive_dyskinesia_ L2 - http://www.diseaseinfosearch.org/result/6999 DB - PRIME DP - Unbound Medicine ER -